Vericel jumps as FDA approves treatment for burns

Vericel

29/12/2022 19:25

** Shares of biopharma co Vericel Corp  VCEL.O  rise ~11%
to$26.79 in afternoon trade 
    ** Israel-based partner Mediwound's  MDWD.O  shares also up
6.6% at $13.72
    ** VCEL says U.S. Food and Drug Administration approved co
and partner's topical burns treatment Nexobrid 
    ** Approval allows use of NexoBrid to remove burn tissue in
adult patients with deep partial and full-thickness thermal
burns
    ** Adds that Nexobrid is expected to be commercially
available in U.S. in Q2 2023    
    ** Including session moves, VCEL down ~33% and MDWD down
~19% YTD 
 (Reporting by Bhanvi Satija in Bengaluru)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))